Literature DB >> 16855124

Process utility in breast biopsy.

J Shannon Swan1, William F Lawrence, Jessica Roy.   

Abstract

PURPOSE: To determine whether the waiting trade-off (WTO) is feasible for differentiating short-term biopsy preferences in an acute situation where anxiety is the symptomatic disease state.
METHODS: 75 women with past experience of either breast core-needle biopsy (CNB), more invasive excisional surgical biopsy (EXB), or both, had telephone WTO assessments. Patients' baseline and test-related anxiety were valued by time trade-off (TTO) used to scale the WTO. Rating scales (RS) were obtained for convergent validity assessment with WTO and TTO.
RESULTS: Data were obtained in 38 women who had both CNB and EXB ("paired") and 20 who had CNB only and 16 who had EXB only ("unpaired"). Patients rated only the procedure(s) they experienced. Median paired and mean unpaired WTO scores indicated patients were willing to wait significantly longer to avoid EXB (P = 0.0003, P = 0.0002, respectively). The waiting time difference between EXB and CNB was 2.1 weeks greater in unpaired data than paired data. RS scores comparing the procedures were significantly different only for paired data (P < 0.05). Median TTO preferences for baseline (1.00) and test anxiety (0.93) obtained in 74 patients were significantly different (P < 0.0001) and consistent with RS. Correlation was noted between WTO and RS (-0.307 to -0.453, P = 0.0205 to 0.0001). The median EXB quality-adjusted life years toll (1.5 quality-adjusted life days) calculated from pooled WTO data (paired and unpaired) from 54 patients is near a threshold in a published model.
CONCLUSION: The WTO is feasible for discriminating preferences for short-term health states in an acute medical scenario where it might have been expected to be impracticable.

Entities:  

Mesh:

Year:  2006        PMID: 16855124     DOI: 10.1177/0272989X06290490

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  14 in total

1.  Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers.

Authors:  Janie M Lee; Pamela M McMahon; Chung Y Kong; Daniel B Kopans; Paula D Ryan; Elissa M Ozanne; Elkan F Halpern; G Scott Gazelle
Journal:  Radiology       Date:  2010-03       Impact factor: 11.105

Review 2.  Incorporating process utility into quality adjusted life years: a systematic review of empirical studies.

Authors:  Victoria K Brennan; Simon Dixon
Journal:  Pharmacoeconomics       Date:  2013-08       Impact factor: 4.981

Review 3.  Methods for measuring temporary health States for cost-utility analyses.

Authors:  Davene R Wright; Eve Wittenberg; J Shannon Swan; Rebecca A Miksad; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 4.  Valuing Meta-Health Effects for Use in Economic Evaluations to Inform Reimbursement Decisions: A Review of the Evidence.

Authors:  Richard De Abreu Lourenco; Marion Haas; Jane Hall; Rosalie Viney
Journal:  Pharmacoeconomics       Date:  2017-03       Impact factor: 4.981

5.  Comparative Assessment of Patient Preferences and Tolerability in Barrett Esophagus Screening: Results From a Randomized Trial.

Authors:  Christopher H Blevins; Jason S Egginton; Nilay D Shah; Michele L Johnson; Prasad G Iyer
Journal:  J Clin Gastroenterol       Date:  2018 Nov/Dec       Impact factor: 3.062

6.  Patient-centered outcomes in imaging: quantifying value.

Authors:  Ruth C Carlos; Diana S M Buist; Karen J Wernli; J Shannon Swan
Journal:  J Am Coll Radiol       Date:  2012-10       Impact factor: 5.532

7.  Quality-of-life assessment of fibroid treatment options and outcomes.

Authors:  Fiona M Fennessy; Chung Yin Kong; Clare M Tempany; J Shannon Swan
Journal:  Radiology       Date:  2011-03-01       Impact factor: 11.105

8.  Initial development of the Temporary Utilities Index: a multiattribute system for classifying the functional health impact of diagnostic testing.

Authors:  J Shannon Swan; Jun Ying; James Stahl; Chung Yin Kong; Beverly Moy; Jessica Roy; Elkan Halpern
Journal:  Qual Life Res       Date:  2010-04       Impact factor: 4.147

9.  Community and patient values for preventing herpes zoster.

Authors:  Tracy A Lieu; Ismael Ortega-Sanchez; G Thomas Ray; Donna Rusinak; W Katherine Yih; Peter W Choo; Irene Shui; Ken Kleinman; Rafael Harpaz; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

10.  Patient and societal value functions for the testing morbidities index.

Authors:  J Shannon Swan; Chung Yin Kong; Janie M Lee; Omosalewa Itauma; Elkan F Halpern; Pablo A Lee; Sergey Vavinskiy; Olubunmi Williams; Emilie S Zoltick; Karen Donelan
Journal:  Med Decis Making       Date:  2013-05-20       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.